Chemoimmunotherapy Followed by Surgery for Oligometastatic Esophagogastric Cancer: (TORO Protocol)

This study (TORO Protocol) tests whether chemotherapy plus immunotherapy, followed by surgery, can be an effective approach for people with esophageal or stomach-junction cancer that has spread to a limited number of sites (called oligometastatic disease — up to 5 lesions in up to 2 organs). **You may be eligible if...** - You have confirmed esophageal or stomach-junction cancer that has spread to no more than 5 sites in up to 2 organs - Those spread sites can potentially be removed by surgery or treated with radiation - You are between 18 and 80 years old - You are in good health (ECOG 0–1) with adequate heart, lung, kidney, and liver function **You may NOT be eligible if...** - Your cancer has spread widely across the abdomen or chest lining - You are pregnant - You have other conditions that make systemic therapy unsafe Talk to your doctor to see if this trial is right for you.